Angiogenesis Inhibitors and Hypertension: Clinical Aspects

Angiogenesis Inhibitors and Hypertension: Clinical Aspects - None

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31245

Enrollment

Registered

2007-06-14

Start date

2008-01-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure hypertension

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Men and women, with either renal cell carcinoma or gastrointestinal stromal tumors (GIST) intended to be treated solely with Sunitinib (single-agent treatment) and who are considered fit enough by their treating physician to receive Sunitinib.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
- Patients developing an increase in blood pressure or not will be compared. The patient*s blood pressure is classified according to the WHO criteria for hypertension in stage 0, stage I, stage II and stage III. - Patients in whom the blood pressure increases at least 10 mmHg or in whom the blood pressure increases from one stage to the next are considered to have a clinically relevant and treatment-induced rise in blood pressure. A subdivision is made between patients with a one-step rise and a two-step rise in stages.	—

Measure

Time frame

- Patients developing an increase in blood pressure or not will be compared. The patient*s blood pressure is classified according to the WHO criteria for hypertension in stage 0, stage I, stage II and stage III. - Patients in whom the blood pressure increases at least 10 mmHg or in whom the blood pressure increases from one stage to the next are considered to have a clinically relevant and treatment-induced rise in blood pressure. A subdivision is made between patients with a one-step rise and a two-step rise in stages.

—

Secondary

Measure	Time frame
None	—

Countries

Netherlands

Outcome results